Brookline Capital Markets analyst Kemp Dolliver reiterated a Buy rating and $1.60 price target on iBio, Inc. (NASDAQ: IBIO).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE